Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

Share Price is delayed by 15 minutes
Get Live Data
22.50    1.00 (4.65%)
Bid:
22.00
Ask:
23.00
Spread: 1.00 (4.545%)
Market Cap: £31.18m
SAR Live PriceLast checked at - London Stock Exchange

Intraday Sareum Share Chart

Corporate update

19 Jun 2008 07:00

RNS Number : 0476X
Sareum Holdings PLC
19 June 2008
 



19 June 2008

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Corporate Update

Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, announced on 2 May 2008, that the Board was undertaking a strategic review to consider how best to take the business forward and create value for shareholders. 

 

On 14 May, the Company announced that as part of the strategic review, the board had implemented a staff restructuring process to reduce its cost base by approximately one third and prepare itself for any potential acquisition or re-financing whilst the future business strategy is under consideration. The restructuring programme has been successfully completed and the Sareum board will continue to review the Company's cost base diligently. In addition, the Company is making progress on a number of fronts and these are described below.

Following announcement of the review on 2 May, Sareum has received expressions of interest in parts or all of its business, particularly its valuable drug discovery programmes, and has received interest in and possible offers to partner, fund, acquire or invest in certain of its programmes or assets. Any transaction resulting from these discussions would lead to an injection of cash into the Company. Initial due diligence is currently being undertaken in respect of several of these discussions. These discussions are at various stages and there is no certainty that any one of them will lead to an offer being made for the Company or any of its assets. The Sareum board continues to actively progress discussions and further announcements will be made as appropriate. 

The Board has concluded, as a result of this review, that the Company should undertake a strategic transaction and it will need to effect a fundraising to enable it to complete such a transaction. In order to facilitate this, the Company will shortly be sending a notice to shareholders convening a general meeting at which shareholders will be asked to give the directors authority to issue further shares for cash. Should the Board decide within a short timescale that strategic transaction is not achievable, the Board will take a decision as to the future of the Company in its present form, as the Company would not be able to continue operations without a significant fundraising.

- Ends-

For further information please contact

Sareum Holdings plc

01223 497700

Tim Mitchell, Chief Executive Officer

 

Buchanan Communications

020 7466 5000

Tim Anderson, Mary-Jane Johnson 

 

Grant Thornton Corporate Finance

020 7383 5100

Philip Secrett, Colin Aaronson

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQVLFFVQBZBBD
Date   Source Headline
12th Sep 20227:00 amRNSSareum notes FDA approval of first TYK2 Inhibitor
28th Jul 20227:00 amRNSCTA application to MHRA and Corporate Update
4th Jul 20227:00 amRNSSareum notes GSK's completed acquisition of Sierra
26th Apr 20227:00 amRNSSareum to Present at BioTrinity 2022 Conference
13th Apr 20224:00 pmRNSSareum notes acquisition of Sierra Oncology by GSK
13th Apr 202211:05 amRNSSecond Price Monitoring Extn
13th Apr 202211:00 amRNSPrice Monitoring Extension
11th Apr 20227:00 amRNSEuropean Patent Granted for Sareum’s SDC-1802
8th Apr 20224:41 pmRNSSecond Price Monitoring Extn
8th Apr 20224:36 pmRNSPrice Monitoring Extension
6th Apr 20222:06 pmRNSSecond Price Monitoring Extn
6th Apr 20222:00 pmRNSPrice Monitoring Extension
16th Mar 20227:00 amRNSSDC-1801: Preclinical Toxicology Report Received
9th Mar 202211:06 amRNSSecond Price Monitoring Extn
9th Mar 202211:00 amRNSPrice Monitoring Extension
28th Feb 20223:50 pmRNSResults of EGM
21st Feb 20227:00 amRNSHalf-year Report
14th Feb 20222:06 pmRNSSecond Price Monitoring Extn
14th Feb 20222:01 pmRNSPrice Monitoring Extension
4th Feb 20227:00 amRNSPublication of Circular; Notice of General Meeting
28th Jan 20228:11 amRNSCorrection - Issue of Warrants
28th Jan 20227:00 amRNSIssue of Warrants
25th Jan 20227:00 amRNSSareum to Participate in Edison Open House Event
17th Dec 20217:00 amRNSSubscription to raise £1.63m to progress SDC-1801
16th Dec 20214:21 pmRNSResult of AGM
16th Dec 20217:00 amRNSAGM Statement
15th Dec 20217:00 amRNSIntention to grant notice - EU patent for SDC-1802
7th Dec 20217:00 amRNSAGM Update
23rd Nov 202112:57 pmRNSDirector/PDMR Shareholding
19th Nov 20217:00 amRNSNotice of AGM
3rd Nov 20213:00 pmRNSExercise of Share Options and Director Dealings
29th Oct 20217:00 amRNSAppointment of Joint Corporate Broker
25th Oct 20217:00 amRNSSareum: Final Results for Year Ended 30 June 2021
21st Oct 20218:32 amRNSCorrection - Notice of Results
21st Oct 20217:00 amRNSNotice of Results and Investor Presentation
7th Oct 202110:42 amRNSUS Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor
29th Sep 202110:46 amRNSReference to SRA737 Timeline at Cantor Conference
19th Aug 20217:00 amRNSTrading Statement
9th Aug 20211:26 pmRNSSubscription to raise £1,000,000
6th Aug 20217:19 amRNSSRA737 update
30th Jul 20217:00 amRNSUS Patent Notice of Allowance for SDC-1802
19th Jul 20212:05 pmRNSSecond Price Monitoring Extn
19th Jul 20212:01 pmRNSPrice Monitoring Extension
19th Jul 202111:13 amRNSSubscription to raise £1,000,000
14th Jul 20217:00 amRNSExercise of Warrants and Total Voting Rights
1st Jul 20217:00 amRNSCovid-19 Research Project Results
24th Jun 20212:05 pmRNSSecond Price Monitoring Extn
24th Jun 20212:00 pmRNSPrice Monitoring Extension
21st Jun 20218:00 amRNSSareum to Present at BioTrinity 2021 Conference
17th Jun 20214:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.